2 Works

Data from: Effectiveness of ritonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens

Patricia Jiménez-Aguilar, Juan Pasquau-Liaño, Pompeyo Viciana, Luis López-Cortés, Miguel López-Ruz, Zaira Palacios-Baena, Dolores Merino Merino, José Fajardo-Pico, José Hernández-Quero, Alberto Terrón-Pernía, Guillermo Ojeda-Burgos, Manuel Marquez-Solero, David Vinuesa-Garcia, Manuel A. Castaño Castaño, María Rios-Villegas, Alberto Romero-Palacios, Francisco Tellez-Pérez, Francisco Orihuela-Cañadas Orihuela-Cañadas, Miguel A. López-Ruz & María J. Rios-Villegas
Background and objective: Significant controversy still exists about ritonavir-boosted protease inhibitor monotherapy (mtPI/rtv) as a simplification strategy that is used up to now to treat patients that have not experienced previous virological failure (VF) while on protease inhibitor (PI)-based regimens. We have evaluated the effectiveness of two mtPI/rtv regimens in an actual clinical practice setting, including patients that had experienced previous VF with PI-based regimens. Methods: This retrospective study analyzed 1060 HIV-infected patients with undetectable...

Effects of high and low-efficacy therapy in secondary progressive multiple sclerosis

Izanne Roos, Emmanuelle Leray, Romain Casey, Dana Horakova, Eva Havrdova, Guillermo Izquierdo, Sara Eichau, Francesco Patti, Gilles Edan, Marc Debouverie, Jean Pelletier, Serkan Ozakbas, Maria Pia Amato, Pierre Clavelou, Pierre Grammond, Cavit Boz, Katherine Buzzard, Olga Skibina, Jonathan Ciron, Oliver Gerlach, Francois Grand'Maison, Jeannette Lechner-Scott, Charles Malpas, Helmut Butzkueven, Sandra Vukusic … & Tomas Kalincik
Objective: To compare the clinical effectiveness of high- and low-efficacy treatments in patients with recently active and inactive secondary progressive multiple sclerosis (SPMS) after accounting for therapeutic lag. Methods: Patients treated with high- (natalizumab, alemtuzumab, mitoxantrone, ocrelizumab, rituximab, cladribine, fingolimod) or low-efficacy (interferon β, glatiramer acetate, teriflunomide) therapies after SPMS onset were selected from MSBase and OFSEP, two large observational cohorts. Therapeutic lag was estimated for each patient based on their demographic and clinical characteristics....

Registration Year

  • 2021
    1
  • 2016
    1

Resource Types

  • Dataset
    2

Affiliations

  • Hospital Universitario Virgen Macarena
    2
  • Dokuz Eylül University
    1
  • University of Newcastle Australia
    1
  • Hospices Civils de Lyon
    1
  • University of Rennes 1
    1
  • Centre Hospitalier Universitaire de Toulouse
    1
  • University of Clermont Auvergne
    1
  • University of Melbourne
    1
  • University of Lyon System
    1
  • Charles University
    1